Detail akcie iCAD online

Business Summary: iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, iCAD Inc revenues decreased 13% to $17.3M. Net loss before extraordinary items decreased 29% to $7M. Revenues reflect Products decrease of 21% to $9.9M. Lower net loss reflects Marketing and sales - Balancing value decrease of 28% to $7.4M (expense), General and administrative - Balancing v decrease of 11% to $8.5M (expense), Interest income increase from $213K to $729K (income).